Protective effects of cationic bovine serum albumin-conjugated PEGylated tanshinone IIA nanoparticles on cerebral ischemia

Biomaterials

Volumn 34, Issue 3, 2013, Pages 817-830

  Liu, Xin ^a   An, Chiying ^b   Jin, Peng ^c   Liu, Xuesong ^a   Wang, Longhu ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^c HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Cationic bovine serum albumin; Cerebral ischemia; Neuroprotection; PEGylated nanoparticles; Tanshinone IIA

Indexed keywords

CATIONIC BOVINE SERUM ALBUMINS; CEREBRAL ISCHEMIA; NEUROPROTECTION; PEGYLATED NANOPARTICLE; TANSHINONE II A;

CONTROLLED DRUG DELIVERY; ENCAPSULATION; IMMUNOLOGY; MAMMALS; PHOSPHORYLATION;

BRAIN;

BOVINE SERUM ALBUMIN; CATIONIC BOVINE SERUM ALBUMIN; GLIAL FIBRILLARY ACIDIC PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; MACROGOL; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; MYELOPEROXIDASE; NANOPARTICLE; NITRIC OXIDE SYNTHASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TANSHINONE IIA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN ISCHEMIA; CONTROLLED STUDY; DISEASE SEVERITY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG SCREENING; DRUG UPTAKE; HISTOPATHOLOGY; MENTAL DEFICIENCY; NANOENCAPSULATION; NEUROPROTECTION; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR UPREGULATION;

ANIMALS; BRAIN; BRAIN ISCHEMIA; CATTLE; DITERPENES, ABIETANE; DRUG CARRIERS; GENE EXPRESSION REGULATION; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-1BETA; INTERLEUKIN-6; NANOPARTICLES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; POLYETHYLENE GLYCOLS; PPAR GAMMA; RATS; RATS, SPRAGUE-DAWLEY; SERUM ALBUMIN, BOVINE; TUMOR NECROSIS FACTOR-ALPHA;

BOVINAE; RATTUS;

EID: 84868482671     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.10.017     Document Type: Article

References (59)

1. Roger V.L., Go A.S., Lloyd-Jones D.M., Benjamin E.J., Berry J.D., Borden W.B., et al. Executive summary: heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation 2012, 125:188-197.
2. Mehta S.L., Manhas N., Raghubir R. Molecular targets in cerebral ischemia for developing novel therapeutics. Brain Res Rev 2007, 54:34-66.
3. Nakka V.P., Gusain A., Mehta S.L., Raghubir R. Molecular mechanisms of apoptosis in cerebral ischemia: multiple neuroprotective opportunities. Mol Neurobiol 2008, 37:7-38.
4. Bernardi A., Frozza R.L., Horn A.P., Campos M.M., Calixto J.B., Salbego C., et al. Protective effects of indomethacin-loaded nanocapsules against oxygen-glucose deprivation in organotypic hippocampal slice cultures: Involvement of neuroinflammation. Neurochem Int 2010, 57:629-636.
5. Allan S.M., Rothwell N.J. Cytokines and acute neurodegeneration. Nat Rev Neurosci 2001, 2:734-744.
6. Saito K., Suyama K., Nishida K., Sei Y., Basile A.S. Early increases in TNF-alpha, IL-6 and IL-1 beta levels following transient cerebral ischemia in gerbil brain. Neurosci Lett 1996, 206:149-152.
7. Vila N., Castillo J., Dávalos A., Chamorro A. Proinflammatory cytokines and early neurological worsening in ischemic stroke. Stroke 2000, 31:2325-2329.
8. Slemmer J.E., Shacka J.J., Sweeney M.I., Weber J.T. Antioxidants and free radical scavengers for the treatment of stroke, traumatic brain injury and aging. Curr Med Chem 2008, 15:404-414.
9. Chen J., Li C., Pei D.S., Han D., Liu X.M., Jiang H.X., et al. GluR6-containing KA receptor mediates the activation of p38 MAP Kinase in rat hippocampal CA1 region during brain ischemia injury. Hippocampus 2009, 19:79-89.
10. Lerouet D., Beray-Berthat V., Palmier B., Plotkine M., Margaill I. Changes in oxidative stress, iNOS activity and neutrophil infiltration in severe transient focal cerebral ischemia in rats. Brain Res 2002, 958:66-75.
11. Roux P.P., Blenis J. ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev 2004, 68:320-344.
12. Walton K.M., DiRocco R., Bartlett B.A., Koury E., Marcy V.R., Jarvis B., et al. Activation of p38 MAPK in microglia after ischemia. J Neurochem 1998, 70:1764-1767.
13. Kaminska B., Gozdz A., Zawadzka M., Ellert-Miklaszewska A., Lipko M. MAPK signal transduction underlying brain inflammation and gliosis as therapeutic target. Anat Rec (Hoboken) 2009, 292:1902-1913.
14. Kovalska M., Kovalska L., Pavlikova M., Janickova M., Mikuskova K., Adamkov M., et al. Intracellular signaling MAPK pathway after cerebral ischemia-reperfusion injury. Neurochem Res 2012, 37:1568-1577.
15. Massimo C., Nimesh S.A.P., Christoph T. PPARs as new therapeutic targets for the treatment of cerebral ischemia/reperfusion injury. Ther Adv Cardiovasc Dis 2008, 2:179-197.
16. Culman J., Zhao Y., Gohlke P., Herdegen T. PPAR-gamma: therapeutic target for ischemic stroke. Trends Pharmacol Sci 2007, 28:244-249.
17. Sundararajan S., Gamboa J.L., Victor N.A., Wanderi E.W., Lust W.D., Landreth G.E. Peroxisome proliferator-activated receptor-gamma ligands reduce inflammation and infarction size in transient focal ischemia. Neuroscience 2005, 130:685-696.
18. Han J.Y., Fan J.Y., Horie Y., Miura S., Cui D.H., Ishii H., et al. Ameliorating effects of compounds derived from Salvia miltiorrhiza root extract on microcirculatory disturbance and target organ injury by ischemia and reperfusion. Pharmacol Ther 2008, 117:280-295.
19. Tang C., Xue H.L., Bai C.L., Fu R., Wu A.H. The effects of Tanshinone IIA on blood-brain barrier and brain edema after transient middle cerebral artery occlusion in rats. Phytomedicine 2010, 17:1145-1149.
20. Fu J., Huang H., Liu J., Pi R., Chen J., Liu P. Tanshinone IIA protects cardiac myocytes against oxidative stress-triggered damage and apoptosis. Eur J Pharmacol 2007, 568:213-221.
21. Du W., Wei Y.H., Zhao G. Simultaneous determination of four tanshinones in rat plasma by high performance liquid chromatography and its application to pharmacokinetic studies. J Chin Pharm 2008, 43:786-790.
22. Chen X., Zhou Z.W., Xue C.C., Li X.X., Zhou S.F. Role of P-glycoprotein in restricting the brain penetration of tanshinone IIA, a major active constituent from the root of Salvia miltiorrhiza Bunge, across the blood-brain barrier. Xenobiotica 2007, 37:635-678.
23. Gabathuler R. Approaches to transport therapeutic drugs across the blood brain barrier to treat brain diseases. Neurobiol Dis 2010, 37:48-57.
24. Parikh T., Bommana M.M., Squillante E. Efficacy of surface charge in targeting pegylated nanoparticles of sulpiride to the brain. Eur J Pharm Biopharm 2010, 74:442-450.
25. Karakoti A.S., Das S., Thevuthasan S., Seal S. PEGylated inorganic nanoparticles. Angew Chem Int Ed 2011, 50:1980-1994.
26. Cimini A., D'Angelo B., Das S., Gentile R., Benedetti E., Singh V., et al. Antibody-conjugated PEGylated cerium oxide nanoparticles for specific targeting of Aβ aggregates modulate neuronal survival pathways. Acta Biomater 2012, 8:2056-2067.
27. Lu W., Wan J., She Z., Jiang X.G. Brain delivery property and accelerated blood clearance of cationic albumin conjugated pegylated NPs. J Control Release 2007, 118:38-53.
28. Huwyler J., Wu D., Pardridge W.M. Brain drug delivery of small molecules using immunoliposomes. Proc Natl Acad Sci USA 1996, 93:14164-14169.
29. Olivier J.C., Huertas R., Lee H.J., Calon F., Pardridge W.M. Synthesis of pegylated immunonanoparticles. Pharm Res 2002, 19:1137-1143.
30. Longa E.Z., Weinstein P.R., Carlson S., Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 1989, 20:84-91.
31. Barone F.C., Schmidt D.B., Hillegass L.M., Price W.J., White R.F., Feuerstein G.Z., et al. Reperfusion increases neutrophils and leukotriene B4 receptor binding in rat focal ischemia. Stroke 1992, 23:1347-1348.
32. Dong Y., Feng S.S. Methoxy poly(ethylene glycol)-poly(lactide) (MPEG-PLA) nanoparticles for controlled delivery of anticancer drugs. Biomaterials 2004, 25:2843-2849.
33. Zhang Y., Zha L., Wang C., Jiang S. Preparation characterization and application of pyrene-loaded methoxy poly(ethylene glycol)-poly(lactic acid) copolymer nanoparticles. Colloid Polym Sci 2004, 282:1323-1328.
34. Bergmann P., Kacenelenbogen R., Vizet A. Plasma clearance, tissue distribution and catabolism of cationized albumin with increasing isoelectric points in the rat. Clin Sci 1984, 67:35-43.
35. Calvo P., Gouritin B., Chacun H., Desmaële D., D'Angelo J., Noel J.P., et al. Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery. Pharm Res 2001, 18:1157-1166.
36. Liu J.P., Zhu J.B., Du Z.Y., Qin B. Preparation and pharmacokinetic evaluation of tashinone IIA solid lipid nanoparticles. Drug Dev Ind Pharm 2005, 31:551-556.
37. Yu J.H., Kim K.H., Kim H. SOCS 3 and PPAR-gamma ligands inhibit the expression of IL-6 and TGF-beta1 by regulating JAK2/STAT3 signaling in pancreas. Int J Biochem Cell Biol 2008, 40:677-688.
38. Jain A.K., Goyal A.K., Mishra N., Vaidya B., Mangal S., Vyas S.P. PEG-PLAPEG block copolymeric nanoparticles for oral immunization against hepatitis B. Int J Pharm 2010, 387:253-262.
39. Xiao R.Z., Zeng Z.W., Zhou G.L., Wang J.J., Li F.Z., Wang A.M. Recent advances in PEG-PLA block copolymer nanoparticles. Int J Nanomedicine 2010, 26:1057-1065.
40. Wei Q., Wei W., Tian R., Wang L.Y., Su Z.G., Ma G.H. Preparation of uniform-sized PELA microspheres with high encapsulation efficiency of antigen by premix membrane emulsification. J Colloid Interface Sci 2008, 323:267-273.
41. Lim Soo P., Cho J., Grant J., Ho E., Piquette-Miller M., Allen C. Drug release mechanism of paclitaxel from a chitosan-lipid implant system: effect of swelling, degradation and morphology. Eur J Pharm Biopharm 2008, 69:149-157.
42. Bazile D., Prud'homme C., Bassoullet M.T., Marlard M., Spenlehauer G., Veillard M. Stealth Me.PEG-PLA nanoparticles avoid uptake by the mononuclear phagocyte system. J Pharm Sci 1995, 84:493-498.
43. Cheyuo C., Jacob A., Wu R.Q., Zhou M., Qi L., Dong W.F., et al. Recombinant human MFG-E8 attenuates cerebral ischemic injury: Its role in anti-inflammation and anti-apoptosis. Neuropharmacology 2012, 62:890-900.
44. Lou H.Y., Zhang X.M., Wei X.B., Wang R.X., Sun X. Anti-inflammatory effect of hydroxyethyl puerarin on focal brain ischemia/reperfusion injury in rats. Chin J Physiol 2004, 47:197-201.
45. Pacher P., Beckman J.S., Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev 2007, 87:315-424.
46. Wang X.L., Liu H.R., Tao L., Liang F., Yan L., Zhao R.R., et al. Role of iNOS-derived reactive nitrogen species and resultant nitrative stress in leukocytes-induced cardiomyocyte apoptosis after myocardial ischemia/reperfusion. Apoptosis 2007, 12:1209-1217.
47. Gao F., Yue T.L., Shi D.W., Christopher T.A., Lopez B.L., Ohlstein E.H., et al. p38 MAPK inhibition reduces myocardial reperfusion injury via inhibition of endothelial adhesion molecule expression and blockade of PMN accumulation. Cardiovasc Res 2002, 53:414-422.
48. Maddahi A., Edvinsson L. Cerebral ischemia induces microvascular pro-inflammatory cytokine expression via the MEK/ERK pathway. J Neuroinflammation 2010, 7:1-14.
49. Jeong S., Kim S.J., Jeong C., Lee S., Jeong H., Lee J.U., et al. Neuroprotective effects of remifentanil against transient focal cerebral ischemia in rats. J Neurosurg Anesthesiol 2012, 24:51-57.
50. Vila N., Chamorro A., Castillo J., Davalos A. Glutamate, interleukin-6, and early clinical worsening in patients with acute stroke. Stroke 2001, 32:1234-1237.
51. Castellanos M., Castillo J., Garcia M.M., Leira R., Serena J., Chamorro A., et al. Inflammation-mediated damage in progressing lacunar infarctions: a potential therapeutic target. Stroke 2002, 33:982-987.
52. Buttini M., Sauter A., Boddeke H.W. Induction of interleukin-1 beta mRNA after focal cerebral ischaemia in the rat. Brain Res Mol Brain Res 1994, 23:126-134.
53. Huang J., Hupadhyay U.M., Tamargo R.J. Inflammation in stroke and focal cerebral ischemia. Surg Neurol 2006, 66:232-245.
54. Xie Z., Smith C.J., Van Eldik L.J. Activated glia induce neuron death via MAP kinase signaling pathways involving JNK and p38. Glia 2004, 45:170-179.
55. Chio C.C., Lin J.W., Chang M.W., Wang C.C., Kuo J.R., Yang C.Z., et al. Therapeutic evaluation of etanercept in a model of traumatic brain injury. J Neurochem 2010, 115:921-929.
56. Pekny M., Nilsson M. Astrocyte activation and reactive gliosis. Glia 2005, 50:427-434.
57. Jander S., Schoroeter M., Stoll G. Role of NMDA receptor signaling in the regulation of inflammatory gene expression after focal brain ischemia. J Neuroimmunol 2000, 109:181-187.
58. Ricote M., Glass C.K. PPARs and molecular mechanisms of transrepression. Biochim Biophys Acta 2007, 1771:926-935.
59. Wang C.X., Ding X., Noor R., Pegg C., He C., Shuaib A. Rosiglitazone alone or in combination with tissue plasminogen activator improves ischemic brain injury in an embolic model in rats. J Cereb Blood Flow Metab 2009, 29:1683-1694.